Bone marrow histopathology following cytoreductive therapy in chronic idiopathic myelofibrosis

被引:20
作者
Thiele, J
Kvasnicka, HM
Schmitt-Graeff, A
Diehl, V
机构
[1] Univ Cologne, Inst Pathol, D-50924 Cologne, Germany
[2] Univ Freiburg, Inst Pathol, D-7800 Freiburg, Germany
[3] Univ Cologne, Med Clin 1, Cologne, Germany
关键词
bone marrow biopsies; idiopathic myelofibrosis; therapeutic regimens; hypoplasia; scleroedema; myelodysplasia; myelofibrosis;
D O I
10.1046/j.1365-2559.2003.01732.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Aims: To analyse systematically therapy-induced lesions of haematopoiesis in chronic idiopathic myelofibrosis (IMF). Methods and results: A total of 759 sequential bone marrow (BM) biopsies (median interval 32 months) were performed in 261 patients with IMF. Besides a control group (symptomatic treatment), monotherapies included busulfan, hydroxyurea and interferon. In all therapy groups hypoplasia of varying degree was a frequent finding and often accompanied by a patchy distribution of haematopoiesis. Most conspicuous was gelatinous oedema showing a tendency to develop discrete reticulin fibrosis (scleroedema). Minimal to moderate maturation defects of megakaryopoiesis and erythroid precursors occurred, but overt myelodysplastic features were most prominent following hydroxyurea and busulfan therapy. Acceleration and blastic crisis were characterized by the appearance of immature and CD34+ progenitor cells. Concerning the dynamics of fibrosis, no differences were observed between controls and the various therapy groups. In 143 patients (55%) without or with little reticulin at onset, an increase in myelofibrosis was detectable that progressed to overt collagen fibrosis. Conclusions: Therapy-related bone marrow lesions in IMF comprise a strikingly variable spectrum that may include aplasia with scleroedema and a patchy distribution of myelodysplastic haematopoiesis associated with progressive myelofibrosis.
引用
收藏
页码:470 / 479
页数:10
相关论文
共 46 条
[1]   The role of interferon-α in the treatment of idiopathic myelofibrosis [J].
Bachleitner-Hofmann, T ;
Gisslinger, H .
ANNALS OF HEMATOLOGY, 1999, 78 (12) :533-538
[2]   The Italian consensus conference on diagnostic criteria for myelofibrosis with myeloid metaplasia [J].
Barosi, G ;
Ambrosetti, A ;
Finelli, C ;
Grossi, A ;
Leoni, P ;
Liberato, NL ;
Petti, MC ;
Pogliani, E ;
Ricetti, M ;
Rupoli, S ;
Visani, G ;
Tura, S .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 104 (04) :730-737
[3]   A PROGNOSTIC CLASSIFICATION OF MYELOFIBROSIS WITH MYELOID METAPLASIA [J].
BAROSI, G ;
BERZUINI, C ;
LIBERATO, LN ;
COSTA, A ;
POLINO, G ;
ASCARI, E .
BRITISH JOURNAL OF HAEMATOLOGY, 1988, 70 (04) :397-401
[4]  
BAROSI G, 1990, EUR J HAEMATOL, V45, P12
[5]  
BAUERMEISTER DE, 1971, AM J CLIN PATHOL, V56, P24
[6]   MYELOFIBROSIS IN CHRONIC MYELOPROLIFERATIVE DISORDERS - INCIDENCE AMONG SUBTYPES ACCORDING TO THE HANNOVER CLASSIFICATION [J].
BUHR, T ;
GEORGII, A ;
CHORITZ, H .
PATHOLOGY RESEARCH AND PRACTICE, 1993, 189 (02) :121-132
[7]   Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens [J].
Buhr, T ;
Büsche, G ;
Choritz, H ;
Länger, F ;
Kreipe, H .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2003, 119 (01) :152-158
[8]   Treatment of essential thrombocythemia with special emphasis on leukemogenic risk [J].
Finazzi, G ;
Barbui, T .
ANNALS OF HEMATOLOGY, 1999, 78 (09) :389-392
[9]  
FRISCH B, 1986, SCAND J HAEMATOL, V36, P38
[10]  
Furgerson JL, 1996, AM J HEMATOL, V51, P137, DOI 10.1002/(SICI)1096-8652(199602)51:2<137::AID-AJH7>3.0.CO